European markets and US stock futures rose on Monday as biotechnology company Moderna said that a Phase 3 study of its mRNA-1273 vaccine candidate (pictured) showed it had a 94.5 per cent efficacy rate. Reuters
European markets and US stock futures rose on Monday as biotechnology company Moderna said that a Phase 3 study of its mRNA-1273 vaccine candidate (pictured) showed it had a 94.5 per cent efficacy ratShow more

Stock markets rise on more positive vaccine news